Ulcerative Colitis: Symptoms, Diagnosis, and Treatment

Roughly a million Americans live with ulcerative colitis, a chronic inflammatory disease of the large intestine that almost always starts in the rectum and extends upward in a continuous pattern. Bloody diarrhea is the calling card — and unlike its cousin Crohn’s, UC stays inside the colon and stays inside the inner lining. That sounds like a tidier disease, but tidy doesn’t mean mild. UC patients face the same fatigue, urgency, hospitalizations, and long-term cancer surveillance as anyone with inflammatory bowel disease (IBD).

The condition typically appears between ages 15 and 30, with a smaller second peak in the 50s and 60s, according to the Crohn’s & Colitis Foundation. This guide covers how UC presents, how doctors confirm it, the modern treatment ladder, when a flare becomes an emergency, and what surgery looks like for the minority of patients who eventually need a colectomy. It is educational only — every treatment decision below belongs to you and your gastroenterologist.

What Ulcerative Colitis Is

UC is a relapsing immune-mediated disease confined to the colon. Inflammation always involves the rectum (proctitis) and may extend further: left-sided colitis stops around the splenic flexure, while extensive colitis or pancolitis goes beyond it. The inflammation stays superficial — limited to the mucosa and submucosa — which is why fistulas and strictures are rare in UC and common in Crohn’s. Per MedlinePlus, UC causes inflammation and ulcers in the lining of the rectum and colon.

The exact cause remains unknown, but the basic model is well established: a genetically susceptible immune system overreacting to gut bacteria in someone whose colonic mucosal barrier is leakier than normal. Smoking, surprisingly, is associated with lower UC risk and symptoms sometimes worsen on cessation — the opposite pattern from Crohn’s disease (this is a statistical association, not a reason to smoke, which causes far greater harm). UC is one of many immune-mediated illnesses covered in our overview of chronic medical conditions.

Symptoms by Severity

Clinicians often describe UC as mild, moderate, or severe. Milder disease tends to mean fewer stools per day, often with intermittent rectal bleeding and no systemic signs. Moderate disease brings more frequent stools with more consistent bleeding and crampy abdominal pain. Severe UC — the kind that often lands patients in the hospital — produces frequent bloody stools plus systemic signs such as fever, a fast heart rate, anemia, and a sharply elevated inflammatory marker (CRP). About half of patients have relatively mild symptoms overall, per MedlinePlus.

Tenesmus (the urgent feeling of needing to pass stool when the rectum is empty) is highly characteristic. So is nocturnal diarrhea, which helps set UC apart from irritable bowel syndrome. Extra-intestinal manifestations occur in a meaningful minority of patients: peripheral arthritis, episcleritis, erythema nodosum, and primary sclerosing cholangitis (PSC). Some manifestations track disease activity; others, like ankylosing spondylitis and PSC, run independent courses.

When to seek emergency care: Call 911 or go to the nearest emergency room if you experience heavy or frequent bloody stools (for example, many bloody stools in a day), severe abdominal distension with pain, a high fever with a rapid heart rate, lightheadedness or fainting on standing, or vomiting that prevents you from keeping fluids down. These can signal toxic megacolon or acute severe UC — both of which require urgent inpatient care and can be life-threatening if delayed. When in doubt, get evaluated; do not wait it out at home.

Diagnosis

UC diagnosis combines history, blood work, stool tests, and colonoscopy. Stool studies rule out infectious colitis (C. difficile, Shigella, Campylobacter, E. coli O157, amoeba) and check fecal calprotectin, a marker that is typically high in active UC. Blood tests may show anemia and an elevated CRP. Colonoscopy with biopsies confirms the diagnosis and defines disease extent — a critical determinant of cancer surveillance frequency later.

Histology shows crypt distortion, crypt abscesses, basal plasmacytosis, and goblet cell depletion. The inflammation is continuous from the rectum upward without the “skip lesions” seen in Crohn’s. According to the NIDDK, both the endoscopic appearance and the biopsy histology should be documented at diagnosis to establish a baseline you can be measured against over time.

Inducing and Maintaining Remission

Therapy hinges on disease severity and extent, and it is always chosen and dosed by a prescriber — the classes below are described for understanding, not for self-treatment, and this article deliberately does not include drug doses or taper schedules.

Aminosalicylates (5-ASA, e.g., mesalamine) are the usual first step for mild-to-moderate disease. Proctitis often responds to topical mesalamine (suppositories or enemas), with oral mesalamine used for left-sided or extensive disease. A substantial share of mild-to-moderate cases reach remission on mesalamine within several weeks.

Corticosteroids are used to bring flares under control. They are intended for short-term use to induce remission — not as long-term maintenance — because of their side-effect profile, and any change to a steroid course must be directed by the prescribing clinician.

Immunomodulators (thiopurines such as azathioprine, and others) are sometimes used to maintain remission or alongside a biologic.

Biologics. Moderate-to-severe disease that fails conventional therapy moves to biologics or small-molecule drugs. FDA-approved biologics for UC include anti-TNF agents (infliximab, adalimumab, golimumab), the gut-selective integrin blocker vedolizumab, the IL-12/23 agent ustekinumab, and newer IL-23p19 antagonists — mirikizumab (Omvoh), risankizumab (Skyrizi), and guselkumab (Tremfya) — that have gained UC approvals in the 2023–2025 window (verify current labeling). Per the American College of Gastroenterology (ACG) guidelines, advanced therapy (biologic monotherapy, or a biologic plus a thiopurine) is preferred for moderate-to-severe disease over prolonged steroids.

JAK inhibitors. Oral Janus kinase inhibitors (tofacitinib, upadacitinib) are approved for UC. These carry an FDA boxed warning — the agency’s most serious warning — covering risks that may include serious infections, blood clots, major cardiovascular events, cancer, and death; they are typically reserved for specific situations and used under close specialist monitoring.

S1P modulators. Sphingosine-1-phosphate receptor modulators — ozanimod (Zeposia) and etrasimod (Velsipity) — are newer oral options for moderate-to-severe UC. Like every drug above, they require prescriber selection, baseline testing, and monitoring.

The practical point: the modern toolkit is broad. If you are still flaring after an adequate trial of first-line therapy, that is a reason to talk with your gastroenterologist about escalating — not to change doses yourself.

Acute Severe Ulcerative Colitis

A minority of patients experience an episode of acute severe UC, historically defined by the Truelove and Witts criteria (frequent bloody stools plus systemic signs such as fever, fast heart rate, anemia, or an elevated inflammatory marker). This is a medical emergency. Standard care is hospitalization with intravenous corticosteroids; a significant fraction of patients do not respond within the first few days and need “rescue” therapy (for example, infliximab or cyclosporine) — or surgery. All of this is managed by an inpatient team, and specific drugs and doses are their call.

Failure to respond to medical rescue within several days is an indication for urgent colectomy. Delaying surgery in steroid-refractory severe UC raises the risk of perforation and death substantially, which is why prompt ER evaluation of a severe flare matters so much.

Surgery: Colectomy and J-Pouch

Total proctocolectomy with ileal pouch-anal anastomosis (the “J-pouch”) is the most common elective surgery in UC. Removing the colon and rectum cures the colonic disease — UC cannot recur in tissue that no longer exists. Most patients do well with the J-pouch, though pouchitis (inflammation of the pouch) affects a large share of patients within a few years and is usually treated with antibiotics such as ciprofloxacin or metronidazole under a doctor’s direction.

Functional outcomes typically settle to several bowel movements per day with the pouch. A small percentage of pouches eventually fail and require conversion to a permanent ileostomy. Quality-of-life data from large series show scores comparable to the general population once patients have adapted. For some patients — particularly older adults or those who prefer it — a permanent ileostomy without a pouch is a reasonable, durable option.

Cancer Surveillance

Long-standing UC raises colorectal cancer risk. Risk climbs after roughly 8 to 10 years of disease; older studies suggested cumulative incidence rising over the following decades, while newer data with better disease control suggest lower contemporary numbers. The Cleveland Clinic and ACG both recommend surveillance colonoscopy starting several years after diagnosis (sooner — often at diagnosis — if PSC coexists), then repeated every one to three years depending on risk, using high-definition white-light or chromoendoscopy to spot subtle dysplasia. Good inflammation control is itself protective, another reason to keep disease in sustained remission.

When to See a Doctor

Bloody diarrhea is never normal. Even a few episodes warrant evaluation, especially if accompanied by urgency, weight loss, or nighttime symptoms. A primary care physician can run initial labs and stool studies, but a gastroenterologist should perform the diagnostic colonoscopy and direct treatment. Once diagnosed, regular follow-up — more frequently during active disease and less often in stable remission — keeps treatment optimized. And remember the emergency signs above: a severe flare is a reason for the ER, not a wait-and-see.

Frequently Asked Questions

Can ulcerative colitis turn into Crohn’s disease?

UC does not transform into Crohn’s, but a small percentage of patients initially diagnosed with UC are reclassified as Crohn’s or indeterminate colitis over time as new findings emerge. Distinguishing the two early matters because surgical options differ — a J-pouch is generally avoided in known Crohn’s.

What foods trigger UC flares?

No single food causes UC, and rigid elimination diets rarely change the disease course. During flares, many patients tolerate low-residue, lactose-light diets better. The Mediterranean dietary pattern has the most evidence for general gut health in IBD, while ultra-processed foods and certain emulsifiers are increasingly studied as possible contributors to inflammation. Work with your care team or a dietitian rather than self-imposing restrictive diets that risk malnutrition.

Is ulcerative colitis a disability?

UC can qualify as a disability under the ADA when symptoms substantially limit work or daily activities. The Social Security Administration recognizes severe IBD with documented complications under its listing for inflammatory bowel disease. Many patients work full-time during remission and may need workplace accommodations during flares.

Does ulcerative colitis affect life expectancy?

With appropriate treatment and surveillance, modern UC is associated with a life expectancy close to normal. Mortality is meaningfully elevated only in patients with severe complications, advanced colorectal cancer at diagnosis, or significant comorbid PSC.

Can UC be cured?

There is no medication that cures UC, but medical therapy can achieve durable remission and mucosal healing, and removing the colon and rectum surgically eliminates the colonic disease. The goal of modern care is sustained remission, not just symptom relief.

Sources

• MedlinePlus (NIH/NLM) — Ulcerative Colitis
• NIDDK (NIH) — Ulcerative Colitis
• Crohn’s & Colitis Foundation — What Is Ulcerative Colitis?
• American College of Gastroenterology — Ulcerative Colitis in Adults (guideline)
• Cleveland Clinic — Ulcerative Colitis